Clinical trial

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

NCT02946632

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-12-01

PhasePHASE3

Study timeline

Study start (unknown)2016-12-01Date precision: month

Registry last updated2016-10-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type IIunresolved

Interventions

triple combination therapyDRUG

Stepwise add-on therapyDRUG

Sponsors & collaborators

Korea University Anam Hospitallead sponsor

AstraZenecacollaborator

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02946632 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.